Investor Presentation
10
Investor presentation First six months of 2022
Rare disease sales were unchanged at constant exchange rates
DKK
billion
Reported Rare disease sales
Growth at CER
12
0%
3%
1%
10
8
6%
3%
-5%
6
Rare blood disorders
•
4
2
0
Total1
Rare
blood
disorders²
Haem.
A
Haem.
B
Novo-
SevenⓇ
Rare
endocrine
disorders³
Rare disease sales driven by global commercial execution
Rare disease sales remain unchanged, driven by:
•
1% sales decline in North America Operations
•
1% sales growth in International Operations
Rare blood disorders sales increased by 3%, driven by:
NovoSevenⓇ
Uptake of launch products EsperoctⓇ and Refixia®
Rare endocrine disorders sales decreased by 5% driven by:
•
North America Operations sales declined by 14%
•
Novo Nordisk is the leading company in the global human
growth disorder market with a value market share of ~34.0%
Source: Quarterly company announcement
1 Total includes "Other Rare disease", which consists of primarily Vagifem® and Activelle®: 2 Comprises NovoSeven®, Novo Eight®, Esperoct®, Refixia® and NovoThirteen®; 3 Primarily NorditropinⓇ.
Note: NovoThirteenⓇ is not shown for Rare blood disorders breakdown, only for the total bar.
Haem. A: Haemophilia A; Haem. B: Haemophilia B; Unless otherwise specified, sales growth is at constant exchange rates
Novo NordiskⓇView entire presentation